B F Hoyer1, T Dörner. 1. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Deutschland, bimba.hoyer@charite.de.
Abstract
BACKGROUND: Improved understanding of the immunopathogenesis of systemic lupus erythematosus (SLE) has paved the way for new specific immune interventions for this inflammatory disease similar to those for rheumatoid arthritis and spondylarthritides. METHODS: New biologics were developed on this basis or are in the process of clinical development and open up new therapy options for patients. In this context belimumab is of particular importance. As an innovative biologic the monoclonal antibody against the cytokine BAFF/BLyS (belimumab) has been approved for the treatment of serologically active SLE. A number of other biologics against other cytokines are in the clinical development phase and appear to be promising for further improvement of the current therapeutic possibilities in SLE. This article addresses the current aspects of immune interventions with biologics for SLE and the specific challenges of this disease.
BACKGROUND: Improved understanding of the immunopathogenesis of systemic lupus erythematosus (SLE) has paved the way for new specific immune interventions for this inflammatory disease similar to those for rheumatoid arthritis and spondylarthritides. METHODS: New biologics were developed on this basis or are in the process of clinical development and open up new therapy options for patients. In this context belimumab is of particular importance. As an innovative biologic the monoclonal antibody against the cytokine BAFF/BLyS (belimumab) has been approved for the treatment of serologically active SLE. A number of other biologics against other cytokines are in the clinical development phase and appear to be promising for further improvement of the current therapeutic possibilities in SLE. This article addresses the current aspects of immune interventions with biologics for SLE and the specific challenges of this disease.
Authors: Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky Journal: Arthritis Rheum Date: 2010-02
Authors: Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta Journal: Arthritis Rheum Date: 2013-09
Authors: Martin Aringer; Frederic Houssiau; Caroline Gordon; Winfried B Graninger; Reinhard E Voll; Eva Rath; Guenter Steiner; Josef S Smolen Journal: Rheumatology (Oxford) Date: 2009-09-11 Impact factor: 7.580
Authors: G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas Journal: Ann Rheum Dis Date: 2007-05-15 Impact factor: 19.103
Authors: Diana Klose; Mira Woitok; Judith Niesen; Roger R Beerli; Ulf Grawunder; Rainer Fischer; Stefan Barth; Rolf Fendel; Thomas Nachreiner Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240